• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

锌指蛋白503反义RNA2（ZNF503-AS2）是一个很有前景的治疗靶点，且与胶质瘤中的免疫微环境相关。

ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma.

作者信息

Wu Yibo, Mu Guangjing, Li Fang, Sun Yanfei, Lin Xiaoying, Liu Xuemeng, Zhao Zhimin, Han Mingzhi, Wang Donghai, Huang Bin, Li Xingang

机构信息

Department of Neurosurgery, Jinan Microecological Biomedicine Shandong Laboratory and Shandong Key Laboratory of Brain Function Remodeling, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Qilu Hospital, Shandong University, Jinan, China.

Shandong Key Laboratory of Brain Function Remodelling, Jinan, China.

出版信息

PLoS One. 2024 Dec 2;19(12):e0314618. doi: 10.1371/journal.pone.0314618. eCollection 2024.

DOI:10.1371/journal.pone.0314618
PMID:39621695
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11611154/
Abstract

BACKGROUND

Glioma is the most common intracranial malignancy, and the available treatment options are poor. Long noncoding RNAs (lncRNAs) have been reported to be involved in the malignant progression of glioma. The role of ZNF503-AS2 in glioma has not been reported.

METHODS

We screened ZNF503-AS2 with upregulated expression in glioblastoma (GBM) by analyzing the TCGA, CGGA and GTEx databases. Single sample gene set enrichment analysis (ssGSEA) was used to calculate the enrichment of immune cells and signaling pathways in glioma samples. Single-cell datasets were used to analyze the distribution of ZNF503-AS2. In vitro experiments were used to investigate the biological function of ZNF503-AS2.

RESULTS

ZNF503-AS2 was highly expressed in glioma and was associated with poor prognosis, malignant progression and infiltration of immunosuppressive cells. Single-cell transcriptomic analysis showed that ZNF503-AS2 was mainly expressed in macrophages and tumor cells. Further analysis revealed that immunotherapy may have better efficacy in patients with low ZNF503-AS2 expression. In vitro experiments showed that knockdown of ZNF503-AS2 reduced the proliferation, invasion and migration ability of glioma cells, induced G2/M cell cycle arrest and promoted apoptosis.

CONCLUSIONS

ZNF503-AS2 might be a valuable biomarker for predicting the prognosis of glioma patients and a potential target for glioma therapy.

摘要

背景

胶质瘤是最常见的颅内恶性肿瘤，现有的治疗选择效果不佳。据报道，长链非编码RNA（lncRNA）参与胶质瘤的恶性进展。ZNF503-AS2在胶质瘤中的作用尚未见报道。

方法

我们通过分析TCGA、CGGA和GTEx数据库，筛选出在胶质母细胞瘤（GBM）中表达上调的ZNF503-AS2。采用单样本基因集富集分析（ssGSEA）计算胶质瘤样本中免疫细胞和信号通路的富集情况。利用单细胞数据集分析ZNF503-AS2的分布。通过体外实验研究ZNF503-AS2的生物学功能。

结果

ZNF503-AS2在胶质瘤中高表达，与预后不良、恶性进展及免疫抑制细胞浸润相关。单细胞转录组分析表明，ZNF503-AS2主要在巨噬细胞和肿瘤细胞中表达。进一步分析显示，ZNF503-AS2表达低的患者接受免疫治疗可能疗效更好。体外实验表明，敲低ZNF503-AS2可降低胶质瘤细胞的增殖、侵袭和迁移能力，诱导G2/M期细胞周期阻滞并促进细胞凋亡。

结论

ZNF503-AS2可能是预测胶质瘤患者预后的有价值生物标志物，也是胶质瘤治疗的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/e742013f2e42/pone.0314618.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/038a16791c1c/pone.0314618.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/f99c36887845/pone.0314618.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/f74ff57a400d/pone.0314618.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/6bba963f76e4/pone.0314618.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/f6576b2ac3eb/pone.0314618.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/ded83271296e/pone.0314618.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/d165c8ec9873/pone.0314618.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/50c3d461ea02/pone.0314618.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/e742013f2e42/pone.0314618.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/038a16791c1c/pone.0314618.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/f99c36887845/pone.0314618.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/f74ff57a400d/pone.0314618.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/6bba963f76e4/pone.0314618.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/f6576b2ac3eb/pone.0314618.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/ded83271296e/pone.0314618.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/d165c8ec9873/pone.0314618.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/50c3d461ea02/pone.0314618.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f0/11611154/e742013f2e42/pone.0314618.g009.jpg

相似文献

1
ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma.锌指蛋白503反义RNA2（ZNF503-AS2）是一个很有前景的治疗靶点，且与胶质瘤中的免疫微环境相关。
PLoS One. 2024 Dec 2;19(12):e0314618. doi: 10.1371/journal.pone.0314618. eCollection 2024.
2
Long non-coding RNA (lncRNA) HOXD-AS2 promotes glioblastoma cell proliferation, migration and invasion by regulating the miR-3681-5p/MALT1 signaling pathway.长链非编码 RNA（lncRNA）HOXD-AS2 通过调节 miR-3681-5p/MALT1 信号通路促进胶质母细胞瘤细胞的增殖、迁移和侵袭。
Bioengineered. 2021 Dec;12(2):9113-9127. doi: 10.1080/21655979.2021.1977104.
3
Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop.长链非编码 RNA LPP-AS2 通过 miR-7-5p/EGFR/PI3K/AKT/c-MYC 反馈环促进胶质瘤发生。
J Exp Clin Cancer Res. 2020 Sep 22;39(1):196. doi: 10.1186/s13046-020-01695-8.
4
Relationship between CTF1 gene expression and prognosis and tumor immune microenvironment in glioma.CTF1基因表达与胶质瘤预后及肿瘤免疫微环境的关系
Eur J Med Res. 2025 Jan 9;30(1):17. doi: 10.1186/s40001-024-02192-w.
5
Integrative analysis of SEPN1 in glioma: Prognostic roles, functional implications, and potential therapeutic interventions.SEPN1在胶质瘤中的综合分析：预后作用、功能意义及潜在治疗干预措施
PLoS One. 2025 Feb 7;20(2):e0318501. doi: 10.1371/journal.pone.0318501. eCollection 2025.
6
Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis.长链非编码RNA HOXA-AS2通过MiR-373/EGFR轴调控恶性胶质瘤行为及血管生成拟态形成
Cell Physiol Biochem. 2018;45(1):131-147. doi: 10.1159/000486253. Epub 2017 Dec 25.
7
Crosstalk between CD180-overexpression macrophages and glioma cells worsens patient survival through malignant phenotype promotion and immunosuppressive regulation.CD180过表达巨噬细胞与胶质瘤细胞之间的串扰通过促进恶性表型和免疫抑制调节恶化患者生存。
Mol Med. 2024 Dec 20;30(1):264. doi: 10.1186/s10020-024-01029-w.
8
The dual role of calnexin on malignant progression and tumor microenvironment in glioma.钙连蛋白在神经胶质瘤恶性进展和肿瘤微环境中的双重作用
Sci Rep. 2024 Dec 28;14(1):30796. doi: 10.1038/s41598-024-81192-6.
9
Exploring the role of LOX family in glioma progression and immune modulation.探索赖氨酰氧化酶（LOX）家族在神经胶质瘤进展和免疫调节中的作用。
Front Immunol. 2025 Apr 9;16:1512186. doi: 10.3389/fimmu.2025.1512186. eCollection 2025.
10
COL8A1 is a potential prognostic biomarker associated with migration, proliferation, and tumor microenvironment in glioma.COL8A1 是一种潜在的预后生物标志物，与胶质瘤中的迁移、增殖和肿瘤微环境有关。
Exp Cell Res. 2024 Jun 1;439(1):114076. doi: 10.1016/j.yexcr.2024.114076. Epub 2024 May 7.

引用本文的文献

1
The influence of physical activity on emotional management ability in college students: a chain mediating role of psychological resilience and health literacy.体育活动对大学生情绪管理能力的影响：心理韧性与健康素养的链式中介作用
BMC Public Health. 2025 Aug 21;25(1):2878. doi: 10.1186/s12889-025-24252-4.
2
Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives.急性髓系白血病、急性淋巴细胞白血病和中枢神经系统肿瘤中的液体活检与表观遗传学特征：诊断与监测视角
Int J Mol Sci. 2025 Aug 5;26(15):7547. doi: 10.3390/ijms26157547.

本文引用的文献

1
TRIM56 promotes malignant progression of glioblastoma by stabilizing cIAP1 protein.TRIM56 通过稳定 cIAP1 蛋白促进胶质母细胞瘤的恶性进展。
J Exp Clin Cancer Res. 2022 Dec 6;41(1):336. doi: 10.1186/s13046-022-02534-8.
2
Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.全面表征 TNFSF14/LIGHT 在人类神经胶质瘤预后和免疫治疗中的作用。
Front Immunol. 2022 Oct 20;13:1025286. doi: 10.3389/fimmu.2022.1025286. eCollection 2022.
3
Advances in immunotherapy for glioblastoma multiforme.
胶质母细胞瘤的免疫治疗进展。
Front Immunol. 2022 Oct 12;13:944452. doi: 10.3389/fimmu.2022.944452. eCollection 2022.
4
Establishment of a prognostic ferroptosis- and immune-related long noncoding RNAs profile in kidney renal clear cell carcinoma.肾透明细胞癌中预后性铁死亡和免疫相关长链非编码RNA特征的建立
Front Genet. 2022 Aug 30;13:915372. doi: 10.3389/fgene.2022.915372. eCollection 2022.
5
Glioma targeted therapy: insight into future of molecular approaches.脑胶质瘤靶向治疗：分子靶向治疗的未来展望。
Mol Cancer. 2022 Feb 8;21(1):39. doi: 10.1186/s12943-022-01513-z.
6
N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.N6-甲基腺苷相关长非编码 RNA 是肿瘤微环境中潜在的重构指标和骨肉瘤的预后标志物。
Front Immunol. 2022 Jan 12;12:806189. doi: 10.3389/fimmu.2021.806189. eCollection 2021.
7
Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.胶质母细胞瘤：代谢与免疫抑制微环境的关系。
Cells. 2021 Dec 14;10(12):3529. doi: 10.3390/cells10123529.
8
The N-Methyladenosine-Modified Pseudogene HSPA7 Correlates With the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma.N6-甲基腺苷修饰的假基因 HSPA7 与肿瘤微环境相关，并预测胶质母细胞瘤对免疫检查点治疗的反应。
Front Immunol. 2021 Jul 20;12:653711. doi: 10.3389/fimmu.2021.653711. eCollection 2021.
9
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
10
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma.癌细胞与免疫细胞的相互作用促使胶质母细胞瘤向间充质样状态转变。
Cancer Cell. 2021 Jun 14;39(6):779-792.e11. doi: 10.1016/j.ccell.2021.05.002. Epub 2021 Jun 3.